Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
L Bazzola, C Foroni, D Andreis, V Zanoni, MR Cappelletti, G Allevi, S Aguggini, C Strina, M Milani, S Venturini, F Ferrozzi, R Giardini, R Bertoni, H Turley, K Gatter, PG Petronini, SB Fox, AL Harris, M Martinotti, A Berruti Show all
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2015
Awarded by Cancer Research UK
This study was partly funded by the FIRM (Fondazione Internazionale per la Ricerca In Medicina), Cremona, Italy. Dr Reynolds acknowledges support from Breakthrough Breast Cancer.